Recent News

• 12.06.2025 - Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
• 12.06.2025 - Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
• 11.19.2025 - Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
• 11.19.2025 - Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
• 11.13.2025 - Aptose Reports Third Quarter 2025 Results
• 11.13.2025 - Aptose Reports Third Quarter 2025 Results
• 11.03.2025 - Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
• 11.03.2025 - Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
• 10.16.2025 - Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
• 10.16.2025 - Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Recent Filings

• 12.05.2025 - PREM14A Preliminary proxy statements relating to merger or acquisition
• 11.25.2025 - 8-K Current report
• 11.19.2025 - EX-99.1 EX-99.1
• 11.19.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 8-K Current report
• 11.03.2025 - EX-99.1 EX-99.1
• 10.16.2025 - 8-K Current report